MGMT and glioblastoma: Thisenzyme confers resistance to therapy by repairing the TMZ-inducedDNA damage, and it is reported to be overexpressed in 40–60%of GBM patients.4 Thus, MGMT has attractedinterest as a therapeutic target in combination with TMZ.